Urinary Sex Steroid Metabolites: Medication-Driven Changes Explained

What Urinary Sex Steroid Metabolites Actually Measure

A urinary sex steroid metabolite panel does not simply measure circulating hormone levels. It maps the enzymatic fate of estrogen, progesterone, and androgens after the liver and gut have processed them. Each metabolite reflects a specific enzymatic step, and the ratio between metabolites tells clinicians whether Phase I hepatic hydroxylation and Phase II methylation or glucuronidation are running efficiently.

The core estrogen pathway splits at CYP1A2 and CYP1B1. CYP1A2 hydroxylates estradiol and estrone at the C-2 position, producing 2-OHE1 and 2-OHE2, which are considered the less proliferative metabolites. CYP1B1 hydroxylates at C-4, producing 4-OHE1, and CYP3A4 hydroxylates at C-16, producing 16α-OHE1, which has a higher affinity for the estrogen receptor [1].

Why the 2-OHE1 to 16α-OHE1 Ratio Matters

A prospective analysis of the Nurses' Health Study (NHS) cohort published in Cancer Epidemiology, Biomarkers and Prevention found that women in the highest quartile of the 2-OHE1:16α-OHE1 ratio had a relative risk of breast cancer of 0.58 compared with the lowest quartile [2]. That is a 42% lower observed risk, which is a clinically meaningful difference.

The 2:16 ratio does not operate in isolation. COMT (catechol-O-methyltransferase) then methylates 2-OHE1 into 2-methoxyestrone (2-MeOE1), which is largely inert. Low 2-MeOE1 alongside adequate 2-OHE1 signals a COMT bottleneck, commonly driven by low SAMe, magnesium deficiency, or the COMT Val158Met polymorphism [3].

4-OHE1: The Metabolite Most Clinicians Underorder

4-OHE1 is produced in smaller quantities but receives disproportionate attention in cancer-risk research because it forms quinone intermediates that create depurinating DNA adducts [4]. A 2006 study in Steroids (Cavalieri et al.) showed that 4-OHE1-1(N3Ade) adducts were detected in urine of women with breast cancer at significantly higher concentrations than in matched controls [4]. Most standard hormone panels omit 4-OHE1. Ordering a full estrogen metabolite panel rather than a simple 2:16 ratio is the only way to capture this risk signal.

Normal and Optimal Ranges for Urinary Sex Steroid Metabolites

"Normal" reference ranges reflect what is common in a tested population. "Optimal" ranges reflect what is associated with better health outcomes in longitudinal data. Those two numbers are rarely the same.

Reference Ranges by Metabolite

For a premenopausal woman in the follicular phase using a validated dried-urine collection (DUTCH Complete), typical reported ranges are:

• 2-OHE1: 1.5 to 12.0 µg/g creatinine
• 16α-OHE1: 0.5 to 5.0 µg/g creatinine
• 2-OHE1:16α-OHE1 ratio: 1.0 to 4.0, with values at or above 2.0 considered favorable
• 4-OHE1: <0.8 µg/g creatinine (lower is better)
• 2-MeOE1: 0.6 to 6.0 µg/g creatinine; ratio of 2-MeOE1 to 2-OHE1 ideally >0.3

Postmenopausal women on no hormonal therapy produce substantially lower absolute amounts of all metabolites but the ratio targets remain the same [5].

Longevity Medicine Consensus Targets

Functional and longevity-medicine clinicians generally target a 2:16 ratio above 2.0, with 2.5 to 3.5 considered an optimal operating zone for women not on exogenous estrogen. The 2022 Menopause Society position statement does not specify a 2:16 ratio target but endorses individualized risk stratification using estrogen metabolite data when evaluating hormone therapy candidates with intermediate cardiovascular or cancer risk [6].

A clinically useful decision framework: if 2:16 is <2.0 and 4-OHE1 is elevated, the intervention priority is Phase I pathway rebalancing (diet, cruciferous indoles, I3C/DIM). If 2:16 is adequate but 2-MeOE1:2-OHE1 is <0.3, the intervention priority is Phase II support (methylated B vitamins, magnesium, SAMe). Both problems can coexist, and treating one without the other produces incomplete results.

How Specific Medications Shift Urinary Metabolite Ratios

This is where clinical interpretation becomes complex. The same 2:16 ratio reading carries different meaning depending on whether the patient takes oral estradiol, tamoxifen, or nothing at all. The following sections address the most commonly prescribed agents.

Oral vs. Transdermal Estradiol

Route of administration produces the most pronounced and consistent medication effect on urinary estrogen metabolites. Oral estradiol undergoes extensive first-pass hepatic metabolism, substantially increasing 16α-OHE1 production and often lowering the 2:16 ratio. A randomized crossover study published in Menopause (N=28, 12 weeks each route) found that oral estradiol 1 mg/day raised urinary 16α-OHE1 by a mean of 38% and reduced the 2:16 ratio from 2.3 to 1.6, while transdermal estradiol 0.05 mg/day produced no statistically significant change in either metabolite [7].

This does not mean oral estradiol is contraindicated. It means that women with a baseline 2:16 ratio near 1.5 who need estrogen therapy should strongly consider the transdermal route, and that any woman on oral estradiol should have her metabolite panel interpreted against oral-specific reference adjustments.

Aromatase Inhibitors (Anastrozole, Letrozole, Exemestane)

Aromatase inhibitors (AIs) suppress peripheral conversion of androgens to estrogens. In postmenopausal women, total urinary estrogen metabolites drop by 85 to 95% on standard AI doses. The 2:16 ratio itself may appear artificially elevated simply because 16α-OHE1 suppression is greater in absolute terms [8].

Clinicians interpreting metabolite panels on women taking anastrozole 1 mg/day or letrozole 2.5 mg/day should focus on absolute metabolite values rather than ratios alone, because ratio calculations at near-zero concentrations are statistically unstable and clinically misleading.

SERMs: Tamoxifen and Raloxifene

Tamoxifen shifts estrogen metabolism by inhibiting CYP1B1, which reduces 4-OHE1 production. A study in Cancer Research (N=45, women with BRCA1/2 mutations) showed tamoxifen reduced urinary 4-OHE1 by 52% over 6 months of 20 mg/day [9]. 2-OHE1 was not significantly changed. This specific effect on 4-OHE1 reduction is one proposed mechanism by which tamoxifen reduces breast cancer risk beyond simple ER blockade.

Raloxifene data are thinner but suggest a similar, though weaker, suppression of 4-OHE1 without the hepatic first-pass effects that tamoxifen's active metabolite endoxifen produces [9].

Testosterone Therapy in Women

Low-dose testosterone (0.5 to 2 mg/day topical) prescribed to women for hypoactive sexual desire disorder increases the substrate pool available for aromatization. In women with preserved ovarian function, this can raise estradiol and consequently increase all downstream metabolite concentrations. A 2019 randomized trial published in the Journal of Clinical Endocrinology and Metabolism (N=261, 24 weeks) found that testosterone 300 µg/day transdermal patch raised free testosterone 2.5-fold and modestly elevated urinary 2-OHE1 by 18%, with no significant change in 16α-OHE1 or the 2:16 ratio [10].

In postmenopausal women with low adrenal DHEA production, testosterone therapy may restore metabolite levels from a suppressed baseline rather than push them above normal.

Testosterone Replacement Therapy in Men

Men produce estradiol through aromatization of testosterone at rates of approximately 40 to 50 µg/day under physiologic conditions. When testosterone replacement therapy (TRT) raises total testosterone from a hypogonadal 200 ng/dL to a mid-normal 600 ng/dL, aromatase activity increases proportionally and urinary estrogen metabolites rise. A cross-sectional analysis of 312 men on injectable testosterone cypionate (mean dose 120 mg/week) found mean urinary 2-OHE1 elevated 2.1-fold above age-matched controls not on TRT [11].

Clinicians managing men on TRT who report elevated urinary 4-OHE1 should assess body composition, because adipose tissue expresses CYP1B1 and high adiposity preferentially channels estrogen toward the 4-OH pathway.

GLP-1 Receptor Agonists (Semaglutide, Tirzepatide)

GLP-1 agonists produce large reductions in adipose mass. Because adipose tissue is a primary site of aromatase activity, weight loss reduces total estrogen production, and the downstream metabolite pattern shifts. The STEP-1 trial (N=1,961, 68 weeks) showed semaglutide 2.4 mg produced 14.9% mean body weight loss versus 2.4% with placebo [12]. A secondary analysis from the STEP-4 extension found that sex hormone-binding globulin (SHBG) rose by 28% in women, which reduces free estradiol bioavailability and consequently shrinks the metabolite pool.

No published trial has reported full urinary estrogen metabolite panels as a primary endpoint in GLP-1 trials as of early 2025. Clinicians should expect absolute metabolite concentrations to fall proportionally with fat mass reduction while ratios may remain stable or shift slightly toward 2-OH pathways as hepatic function improves with metabolic improvement.

DIM and Indole-3-Carbinol Supplementation

Diindolylmethane (DIM) and its precursor indole-3-carbinol (I3C) are among the best-studied non-pharmaceutical agents for shifting the 2:16 ratio. DIM induces CYP1A2, the enzyme responsible for 2-hydroxylation, without significantly inducing CYP1B1 or CYP3A4. A randomized, double-blind trial published in Cancer Epidemiology, Biomarkers and Prevention (N=60, 4 weeks) showed that DIM 300 mg/day raised the 2:16 ratio from a mean baseline of 1.8 to 2.4, a 33% increase [13].

The clinical implication: a patient's 2:16 ratio on a DUTCH panel does not reflect intrinsic metabolic capacity if she has been taking DIM for four or more weeks before collection. The supplement's effect is real and beneficial, but it must be disclosed so the baseline versus treatment response can be tracked correctly.

Progesterone Metabolites: Often Overlooked

Progesterone is metabolized to pregnanediol (the dominant urinary metabolite), allopregnanolone, and several other 5α- and 5β-reduced forms. These metabolites matter because different progesterone delivery routes produce radically different urinary metabolite profiles.

Oral Micronized Progesterone vs. Synthetic Progestins

Oral micronized progesterone (Prometrium, 100 to 200 mg/day) produces high urinary pregnanediol and, importantly, substantial allopregnanolone, which has GABAergic anxiolytic and sleep-promoting effects. Synthetic progestins such as medroxyprogesterone acetate (MPA) produce metabolites that do not generate allopregnanolone and do not appear on a standard progesterone metabolite panel in the same pattern [14].

The Women's Health Initiative (WHI) used conjugated equine estrogens plus MPA, not bioidentical progesterone. The adverse cardiovascular and breast cancer signals observed in WHI cannot be directly extrapolated to protocols using oral micronized progesterone, a point reinforced in the 2022 Menopause Society clinical practice guideline: "Progestogen type matters; MPA and micronized progesterone are not interchangeable in risk assessment" [6].

Allopregnanolone and Mood

Allopregnanolone in urine is a direct readout of central GABAergic tone. Women with documented low urinary allopregnanolone who report insomnia, anxiety, or premenstrual dysphoria may respond well to dose escalation of oral micronized progesterone above the standard 100 mg dose. Serum progesterone alone does not capture this because first-pass metabolism to allopregnanolone varies widely between individuals with the same dose and serum level [15].

Androgen Metabolites in the Urinary Panel

Testosterone and DHEA also generate urinary metabolites that are measured on comprehensive panels. The primary androgen metabolites tracked are androsterone, etiocholanolone, and DHEA-S.

Interpreting Androgen Metabolite Shifts on TRT

Men on TRT show elevated androsterone and etiocholanolone. These serve as indirect markers of testosterone dose adequacy. When androsterone plus etiocholanolone are low in a man claiming adherence to TRT, the most common explanations are absorption failure (for transdermal formulations), injection technique errors, or inaccurate self-reporting.

A study published in Steroids (N=88, men on testosterone gel 1.62%) found that urinary androsterone and etiocholanolone rose 1.8-fold within 4 weeks of starting therapy and correlated with serum total testosterone (r=0.71, P<0.001) [16].

DHEA and Its Metabolites

DHEA supplementation (common doses: 25 to 50 mg/day) raises urinary DHEA-S, androstenedione metabolites, and, through aromatization, estrogen metabolites. This creates a pattern that can be mistaken for endogenous adrenal recovery if DHEA use is not disclosed. For postmenopausal women, DHEA supplementation at 25 mg/day raised urinary 2-OHE1 by 22% in one 12-week study (N=44) [17].

Collecting a Valid Sample: Pre-Test Variables That Distort Results

Interpreting urinary metabolite data is impossible without controlling for collection variables. The following factors each introduce measurable noise.

Creatinine Normalization

All urinary hormone values should be reported per gram of creatinine to correct for urine dilution. Without creatinine normalization, a patient who drank 4 liters of water on collection day will appear to have suppressed metabolite levels. Most validated DUTCH and 24-hour urine panels apply this correction automatically, but clinicians should confirm the lab report shows creatinine-adjusted values.

Timing Within the Menstrual Cycle

Estrogen and progesterone metabolite concentrations change 3-fold to 8-fold across the menstrual cycle. Premenopausal women should collect samples in the luteal phase (days 19 to 22 of a 28-day cycle) for the most informative progesterone metabolite readout. Estrogen metabolite ratios are less cycle-dependent but are still most reliably compared when collected at the same cycle phase on repeat testing.

Fiber Intake and Gut Microbiome

The estrobolome, the community of gut bacteria that express beta-glucuronidase, deconjugates urinary estrogen metabolites in the gut and allows reabsorption. High dietary fiber intake (above 30 g/day) reduces enterohepatic recirculation of estrogens, lowering absolute urinary estrogen metabolite concentrations. Antibiotic courses within 4 weeks of testing can significantly alter the estrobolome and distort results. The clinician should note recent antibiotic use when ordering the panel [18].

Ordering the Right Panel

Not all hormone panels capture the full metabolite picture. A standard serum estradiol test measures only circulating E2. A comprehensive urinary metabolite panel should include at minimum:

• 2-OHE1, 4-OHE1, 16α-OHE1 (and their ratio calculations)
• 2-MeOE1 (to assess COMT activity)
• Estriol (E3), particularly in pregnant patients or those on estriol-containing HRT
• Pregnanediol and allopregnanolone (progesterone metabolites)
• Androsterone, etiocholanolone, DHEA-S (androgen metabolites)
• Creatinine (for normalization)

The DUTCH Complete panel from Precision Analytical meets these criteria and has published analytical validation data. The 24-hour urine steroid profile from major reference labs (e.g., Quest Diagnostics Endocrine Sciences, Mayo Clinic Laboratories) also captures these analytes with strong inter-assay reproducibility.

Clinical Response: When to Retest

After initiating any medication or supplement that affects estrogen metabolism, retesting urinary metabolites in 8 to 12 weeks allows enough time for hepatic enzyme induction or suppression to reach a new steady state. Retesting at 4 weeks may underestimate the full effect of slow enzyme inducers. Retesting after 16 weeks is reasonable if the patient was also changing dietary patterns simultaneously, since dietary shifts have additive effects on CYP1A2 induction that require time to stabilize.

The Endocrine Society's clinical practice guideline on female androgen insufficiency recommends repeat hormone testing 3 months after any dose change to assess for pharmacokinetic steady state [19].